Vivione Biosciences Inc. announced the execution of an Option Agreement with the University of Rochester to gain exclusive worldwide rights to a novel biomarker for infectious disease-related diagnostics. This acquisition is one of many steps the company is taking to strategically position the company's entry into the clinical diagnostics market. Through the Option Agreement, the company will also have the ability to obtain exclusive worldwide rights to a therapeutic peptide targeting the same molecule identified by the biomarker.

During the option period, the company will work with researchers at the University of Rochester in the Departments of Immunology and Pulmonology in order to expand upon existing data in clinical patient populations.